This study is a multicenter, prospective, interventional study. It does not have a control group. All participants will receive 160 mg valsartan for 8 weeks. Among them, the patients with persistent proteinuria (defined as proteinuria more than 1 g/g after 8 weeks treatment of valsartan) will receive 320 mg valsartan for further 16 weeks. Participants who did not receive any ACEI or ARB previously will have a titration period for 4 weeks (80 mg for 4 weeks, 160 mg for 4 weeks, and then 320 mg for 16 weeks).

The investigators will evaluate the change of urinary angiotensinogen excretion between at baseline, at 8 weeks, and 24 weeks.

Inclusion Criteria:

• Chronic kidney disease patients with

  • proteinuria of 1 - 10 g/day,
  • stable and controlled blood pressure (100/60 mmHg - 160/100 mmHg),
  • stable renal function with GFR ≥ 30 mL/min/ m2,
  • diabetes or non-diabetes

Exclusion Criteria:

• Uncontrolled diabetes (defined as HbA1c > 9.0%)
• Immunosuppressive treatment within 6 months
• Intractable edema
• Hyperkalemia (>5.5 mEq/L) or Hypokalemia (< 3.5 mEq/L)